ModifiedColorado Rocky Mountain Health PlansPolicy SRST2026T0586T

Carrier Testing Panels for Genetic Diseases

Customize your policy alerts

Sign up for Colorado Rocky Mountain Health Plans Policy SRST2026T0586T alerts

Get alerted when Policy SRST2026T0586T changes without checking for updates manually.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

Defines coverage and medical necessity criteria for reproductive carrier screening panels and pan-ethnic carrier screening, and guidance for providers ordering these tests under Colorado Rocky Mountain Health Plans.

Policy Summary

PayerColorado Rocky Mountain Health Plans

PolicyCarrier Testing Panels for Genetic Diseases

Policy CodePolicy SRST2026T0586T

Change TypeCodes removedsupporting sections updated

Effective DateAug 1, 2026

Last ReviewAug 1, 2026

Next Review Date

Key ActionVerify member benefits and prior authorization requirements with the member's plan before ordering carrier screening.

SourceLink

OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

ModifiedColorado Rocky Mountain Health PlansPolicy SRST2026T0586T

Carrier Testing Panels for Genetic Diseases

Customize your policy alerts

Sign up for Colorado Rocky Mountain Health Plans Policy SRST2026T0586T alerts

Get alerted when Policy SRST2026T0586T changes without checking for updates manually.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

Policy Summary

PayerColorado Rocky Mountain Health Plans

PolicyCarrier Testing Panels for Genetic Diseases

Policy CodePolicy SRST2026T0586T

Change TypeCodes removedsupporting sections updated

Effective DateAug 1, 2026

Last ReviewAug 1, 2026

Next Review Date

Key ActionVerify member benefits and prior authorization requirements with the member's plan before ordering carrier screening.

SourceLink

POLICY UPDATE CHANGES

CPT code 81443 was removed from the list of applicable codes.

Description of Services, Clinical Evidence, and References sections were updated to reflect the most current information.

Medical Records Documentation Used for Reviews section was removed.

up to 6 genespanels proven and medically necessary

up to 15 genespanels with specified criteria

16+ genespanels considered unproven

113 genesACMG Tier 3 referenced

63,000+real-world couples

Coverage Criteria

Reproductive Carrier Screening - Covered Criteria

Covered when ALL of the following are met for specified panel sizes:

Panels up to 6 genes: Reproductive carrier screening panels of up to six genes are proven and medically necessary.<=6 genes

Reproductive Carrier Screening panels of up to six genes are proven and medically necessary.

Panels up to 15 genes with risk criteria: Reproductive carrier screening panels of up to 15 genes are proven and medically necessary when the individual and/or their reproductive partner has Ashkenazi Jewish ancestry (at least one parent or grandparent of AJ descent) OR a biological first-degree or second-degree relative affected by one or more of the conditions evaluated by the panel.<=15 genes plus ancestry or family history

Ashkenazi Jewish ancestry defined as at least one parent or grandparent of AJ descent; family history includes a biological first- or second-degree relative affected by a condition on the panel.

Not Medically Necessary

Panels >=16 genes: Reproductive carrier screening panels comprising 16 or more genes are unproven and not medically necessary due to insufficient evidence of efficacy.>=16 genes

Reproductive Carrier Screening panels comprising 16 or more genes are unproven and not medically necessary.

Carrier screening for other indications: Carrier screening for indications outside the reproductive carrier screening criteria above is unproven and not medically necessary.other indications

Carrier Screening for all other indications outside the reproductive carrier screening criteria is considered unproven and not medically necessary.

Carrier screening performed for indications outside the defined reproductive carrier screening population is considered unproven and not medically necessary. The policy specifies that reproductive carrier screening panels of up to six genes are proven and medically necessary, and panels of up to 15 genes may be medically necessary when ancestry or qualifying family history criteria are met; anything beyond these reproductive screening criteria (including indications not related to reproductive risk assessment) is not covered. Carrier Screening for all other indications therefore falls outside covered criteria.

Several large cohort studies excluded individuals with a personal or family history of the disease or reported consanguinity, and many analyses used commercial testing populations that may not represent general populations. These study design features limit generalizability of reported detection rates and may produce referral or selection bias; the policy notes these limitations when considering evidence for broad panel use.

The Royal College of Obstetricians and Gynaecologists (RCOG) states there is insufficient evidence to support routine testing of all prospective parents. RCOG recommends targeted carrier screening for individuals at high risk and emphasizes that clinicians should understand the specific panel used and that interpretation should be performed by clinicians with appropriate genetics expertise.

Reproductive carrier screening panels that include 16 or more genes are considered unproven and not medically necessary due to insufficient evidence of efficacy. The policy therefore restricts coverage for larger panels and designates panels ≥16 genes as excluded from coverage.

Covered Indications

Reproductive carrier screening (preconception or prenatal) for assessing risk of autosomal recessive and X-linked conditions that may affect offspring.

Indication: Testing is performed preconception or prenatal to assess risk of autosomal recessive and X-linked conditions that may affect offspring.

Panel size guidance: Panels up to 6 genes are covered; panels up to 15 genes are covered only when ancestry or family-history criteria are met (see covered criteria).

Recommended inclusions: Panels should include screening for cystic fibrosis (CFTR) and spinal muscular atrophy (SMN1).

Carrier screening focused on individuals of Ashkenazi Jewish descent.

Not Covered

Not covered: Reproductive carrier screening panels comprising 16 or more genes and carrier screening performed for indications other than the reproductive carrier screening criteria defined in this policy. The policy requires panels beyond routinely covered sizes or outside reproductive indications to meet coverage criteria described elsewhere to be considered.

Not covered: Targeted genotyping-only panels are discouraged because they may miss pathogenic variants compared with sequencing approaches. Studies using targeted genotyping reported lower detection of some variants, and reliance on small ethnicity-based panels can fail to detect many carriers identified by pan-ethnic expanded carrier screening.

Not covered: Routine universal testing of all prospective parents is not recommended by RCOG because evidence is insufficient to support population-wide screening. Panels that are not clinically validated or lack standardization may also be discouraged; interpretation should be carried out by clinicians with appropriate genetics expertise.

Coding and Applicable Codes

Applicable CPT/Procedure CodesCPT

0400U	Obstetrics (expanded carrier screening), 145 genes by next generation sequencing, fragment analysis and multiplex ligation dependent probe amplification, DNA, reported as carrier positive or negative.
81412	Ashkenazi Jewish associated disorders genomic sequence analysis panel, must include sequencing of at least 9 genes, including ASPA, BLM, CFTR, FANCC, GBA, HEXA, IKBKAP, MCOLN1, and SMPD1.
81479	Unlisted molecular pathology procedure

Applicable Codes RemovedCPTNot Covered

81443

CPT code removed from applicable codes

Carrier frequency thresholds referenced

ACOG conservative thresholdInclude conditions with carrier frequency of at least 1 in 100 (correlates with disease incidence ~1 in 40,000).

ACMG tier-based considerationACMG Tier 3 includes conditions with carrier frequency >= 1 in 200 and recommends a one-size-fits-all panel of 113 genes (ACMG Tier 3 recommendation referenced).

Modeling validationLarge data-driven panels increase ARC detection; modeled panels of 152, 248, 531, and 725 genes reach ~90%, 95%, 99%, and 99.7% modeled yields respectively (validated with real-world data).

Actionable threshold (most relevant)Policy references ACOG recommendation to include conditions with carrier frequency >= 1 in 100 as a practical inclusion threshold for panels.

Provider Actions and Documentation

Billing Rule

Procedure codes and panel-size requirements

Applicable procedure codes for expanded carrier screening and related panels are listed for reference: CPT 0400U (expanded carrier screening, 145 genes, NGS), 81412 (Ashkenazi Jewish associated disorders genomic sequence analysis panel, ≥9 genes), and 81479 (unlisted molecular pathology). Panels that exceed the policy's allowable sizes (see denial risk) may be restricted or considered not medically necessary.

List of applicable CPT/procedure codes: 0400U, 81412, 81479
Policy notes panels up to 6 genes are proven and medically necessary; up to 15 genes may be covered with ancestry or family history criteria; panels ≥16 genes are unproven/not medically necessary.

Prior Authorization

Justify large/sequence‑based panels

Eligibility Requirements

Coverage for panels up to 15 genes is conditional: the individual or their reproductive partner must have either documented Ashkenazi Jewish ancestry (at least one parent or grandparent of AJ descent) or a biological first- or second-degree relative affected by one or more of the conditions on the panel. Documentation of the qualifying ancestry or family history is required to support coverage for these panel sizes.

Some published studies specifically excluded participants with prior personal or family history of disease or prior screening; however, the policy does not mandate prior testing before expanded carrier screening. The literature shows varied inclusion criteria across cohorts, and absence of required prior testing is reflected in the policy's eligibility approach.

Multiple studies excluded individuals with a family or personal history when estimating population carrier rates; despite these exclusions, expanded carrier screening is commonly applied in clinical practice without explicit prior-testing prerequisites. The policy therefore focuses eligibility on ancestry and affected relative criteria for certain panel sizes rather than requiring prior targeted testing.

Evidence cohorts frequently excluded persons with known disease or consanguinity, and many results derive from commercial laboratory populations. These study limitations mean that clinical utility and yield observed in those cohorts may not apply to all clinical settings, and the policy does not impose prior testing requirements based solely on these studies.

Background

Carrier screening identifies asymptomatic individuals who may carry pathogenic variants for autosomal recessive or X-linked disorders that could be passed to offspring. The policy aligns with professional guidance by recommending inclusion of cystic fibrosis (CFTR) and spinal muscular atrophy (SMN1) in reproductive carrier screening panels and by defining covered panel sizes and qualifying criteria for expanded panels.

Definitions

Carrier Screening

DefinitionGenetic testing performed on an asymptomatic individual to determine whether they may have a genetic variant associated with a disorder that could be passed to biological children.

PurposeIdentify carrier status for autosomal recessive and X-linked conditions to inform reproductive decision-making.

RecommendationPretest genetic counseling is strongly recommended to inform persons about advantages and limitations (see policy counseling requirements).

Gene Panel

DefinitionA testing panel that looks for genetic changes/variants in more than one gene in the same test.

MethodologiesPanels frequently use next-generation sequencing or targeted genotyping depending on panel design and lab platform.

Provider Actions — Additional Notes

Documentation Required

Provide and document pretest genetic counseling

Pretest genetic counseling is strongly recommended to inform patients about advantages and limitations of carrier screening; document that counseling was provided or that counseling resources were offered.

Include counseling notes or referral to genetic counseling in the record prior to testing.

Note

No specific ordering provider restriction; ensure genetics support

The policy does not impose explicit restrictions on which provider type may order testing; however, genetic counseling is emphasized and providers should ensure appropriate counseling is available.

If a non-genetics provider orders testing, document availability of genetics expertise for result interpretation and counseling.

Revision History & Policy Changes

08/01/2026code_removalLatest

CPT code 81443 was removed from the list of applicable codes; claims submitted with that code after removal may be affected or denied.

Policy Summary

PayerColorado Rocky Mountain Health Plans

PolicyCarrier Testing Panels for Genetic Diseases

Policy CodePolicy SRST2026T0586T

Change TypeCodes removedsupporting sections updated

Effective DateAug 1, 2026

Last ReviewAug 1, 2026

Next Review Date

Key ActionVerify member benefits and prior authorization requirements with the member's plan before ordering carrier screening.

SourceLink

On This Page

Target population: Individuals of Ashkenazi Jewish (AJ) descent (majority of Jewish ancestry in North America) or reproductive partners thereof.

Panel composition: AJ carrier screening panels may include testing for one or more AJ-associated disorders such as Tay-Sachs disease, Canavan disease, cystic fibrosis (CF), spinal muscular atrophy (SMA), familial dysautonomia, Bloom syndrome, Fanconi anemia, Niemann-Pick disease, Gaucher disease, and mucolipidosis IV.

When covered: AJ-focused panels are considered medically appropriate when the individual or reproductive partner meets AJ ancestry criteria as defined in policy.

Preconception or prenatal carrier screening to identify carriers and at-risk couples for reproductive decision-making.

Purpose: Testing aims to identify carriers and at-risk couples (ARCs) to inform reproductive decision-making, including options such as prenatal diagnostic testing or preimplantation genetic testing.

Timing consideration: Preconception results more frequently lead to active reproductive interventions (e.g., PGT) compared with results returned during pregnancy; offering screening preconception is appropriate when feasible.

Guideline support: Professional guidance (NSGC, ACOG, ACMG) supports offering carrier screening to individuals considering reproduction or who are pregnant, with counseling and shared decision-making.

Individuals planning a pregnancy or pregnant individuals and their partners for carrier screening of CF, SMA, hemoglobinopathies and Tier 3 (>=1/200) conditions per ACMG/ACOG/NSGC guidance.

Who should be offered: Individuals planning a pregnancy, pregnant individuals, and their reproductive partners should be offered carrier screening for cystic fibrosis (CF), spinal muscular atrophy (SMA), and hemoglobinopathies per ACOG; ACMG recommends Tier 3 (carrier frequency >= 1 in 200) screening be offered to all pregnant individuals and those planning pregnancy.

Hemoglobinopathy testing: ACOG recommends offering hemoglobinopathy testing (e.g., hemoglobin electrophoresis or molecular testing) to all individuals planning pregnancy or at first prenatal visit if no prior testing has been performed.

Counseling requirement: Genetic counseling is emphasized for all individuals undergoing carrier screening to explain benefits, limitations, and potential outcomes.

When ordering large or sequencing‑based carrier screening panels, document availability of genetic counseling resources and justify the clinical need for broad genomic testing due to potential workflow burden and low ARC yield reported in some studies.

Document pre/post-test counseling availability (study reported median 64 minutes counselor prep time)
Provide clinical justification for genomic sequencing–based screening given limited incremental actionable findings in some cohorts

Prior Authorization

Verify coverage and prior authorization

Verify the member’s benefit plan coverage and any prior authorization requirements with the plan before ordering carrier screening to ensure services meet member‑specific benefits and applicable mandates.

Confirm member-specific benefit plan and any prior authorization requirements prior to testing
Policy inclusion of codes is for reference only and does not guarantee coverage or reimbursement

Note

Step therapy: not applicable

Not applicable — no step therapy requirements are specified in the provided policy text.

Step Therapy

Preference for pan‑ethnic ECS vs ethnicity‑based panels

Prefer pan‑ethnic expanded carrier screening (ECS) over ethnicity‑based limited panels when clinically appropriate, as multiple studies show higher carrier detection rates with ECS compared with ethnicity‑based screening.

ECS identified substantially more carriers and carrier couples in cohort studies vs ethnicity‑based panels
Consider pan‑ethnic ECS especially when self‑reported ethnicity is unreliable

Note

No additional provider action specified

(No content provided in source to populate this callout.)

Documentation Required

Document pretest genetic counseling

Pretest genetic counseling is strongly recommended and documentation of counseling or counseling availability is advised, particularly for larger sequencing‑based panels, to inform patients of the advantages and limitations of testing.

Document that pretest genetic counseling was provided or was available
For large panels, note counseling resource availability due to increased follow‑up burden

Documentation Required

Document ancestry and family history

Document accurate ancestry and family history (first‑ or second‑degree affected relatives) when relevant — coverage for panels up to 15 genes requires Ashkenazi Jewish ancestry or a biological first‑ or second‑degree relative affected by a panel condition.

Record ancestry (e.g., Ashkenazi Jewish parent or grandparent) when claiming eligibility for up to 15‑gene panels
Document affected biological first‑ or second‑degree relative when applicable

Documentation Required

Check member benefits and document rationale

Before applying this policy, check the member‑specific benefit plan and any applicable federal or state mandates; the policy is informational and UnitedHealthcare may use third‑party tools in administering benefits.

Verify member benefits and legal mandates before relying on policy for coverage decisions
Be aware policy listings of codes are reference only and do not guarantee reimbursement

Denial Risk

Denial risk for panels ≥16 genes

Reproductive carrier screening panels that include 16 or more genes are considered unproven and not medically necessary and may be denied; avoid ordering panels ≥16 genes without explicit medical justification and verification of coverage.

Panels comprising 16 or more genes are listed as unproven and not medically necessary
Orders for ≥16‑gene panels risk claim denial if not supported by applicable exceptions or prior authorization

Denial Risk

Test selection and documentation concerns

Be aware that targeted genotyping panels and some commercial testing cohorts may miss pathogenic variants or reflect referral bias; incomplete or inaccurate ancestry/family history reporting can lead to inappropriate test selection and potential coverage denial.

Targeted genotyping may miss pathogenic variants compared with sequencing
Document clinical indication and ancestry/family history to support test selection and minimize risk of denial

Billing Rule

Coding removal may affect claims

CPT code 81443 was removed from the policy’s applicable codes list; claims submitted using removed codes may be impacted and could be denied if submitted after the code’s removal date.

Policy history notes CPT code 81443 was removed effective 08/01/2026
Ensure claims use currently listed procedure codes (e.g., 0400U, 81412, 81479)

Use caseEmployed in expanded carrier screening (ECS) and ancestry/ethnicity-specific screening panels.

First‑Degree Relative

DefinitionFirst-degree relatives include parents, siblings, and children.

Coverage relevancePresence of an affected first-degree relative can qualify an individual for coverage of panels up to 15 genes per policy criteria.

Clinical noteAscertainment of first-degree family history should be documented when used to justify panel selection under policy rules.

Second‑Degree Relative

DefinitionSecond-degree relatives include half-siblings, aunts, uncles, grandparents, grandchildren, and nieces/nephews.

Coverage relevanceAffected second-degree relatives can be used to meet the policy criteria for coverage of panels up to 15 genes.

DocumentationDocument biological relationship and condition when using second-degree family history to support testing.

ECS (expanded carrier screening)

DefinitionMultigene carrier screening panels (ranging from tens to hundreds of genes) offered pan‑ethnically to identify carrier status for autosomal recessive and X‑linked conditions.

Panel sizes observedPublished panels referenced in the policy include designs from ~37–176 conditions up to several-hundred gene panels (examples: 110, 176, 274 genes).

RationaleECS mitigates limitations of self‑reported ethnicity and increases detection of carriers and at‑risk couples across diverse ancestries.

ARC (at‑risk couple)

DefinitionA reproductive couple in which both partners carry pathogenic variants in the same autosomal recessive gene or where the partner carries a pathogenic X‑linked variant, creating risk for an affected pregnancy.

DetectionLarge‑scale ECS cohorts and sequencing approaches identify ARCs at varying rates depending on panel composition; models and cohorts validate increased ARC detection with larger panels.

Clinical implicationIdentification of an ARC can inform reproductive management including prenatal diagnosis, preimplantation genetic testing, or other options.

Self‑reported ethnicity

ConceptSelf‑reported ethnicity is the race/ethnicity reported by the individual, which can differ from genetic ancestry determined by genomic data.

LimitationsSelf‑reported ethnicity is unreliable for estimating carrier rates and residual risk; discrepancies occur across many ethnic labels and admixed populations.

Policy implicationBecause self‑reporting is unreliable, the policy supports pan‑ethnic ECS to reduce missed carriers and improve risk estimates.

Note

Document ordering/referring provider and indication

No explicit provider‑type ordering restrictions are specified in the policy text; studies referenced included referrals from fertility specialists, obstetricians/gynecologists, and genetic counselors.

Document referring provider and reason for referral when applicable.

Note

Ensure ordering clinicians document counseling availability

No explicit provider‑type ordering restrictions are specified; ensure ordering clinicians document counseling resources and clinical indication when appropriate.

Record availability of counseling and specific clinical justification for testing.